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Summary       
The economic impact on individuals with breast cancer is not well understood. We 
sought to identify and describe the direct and indirect economic losses to breast 
cancer survivors in Australia.  A longitudinal, population-based study of 287 women 
was used to explore economic outcomes (costs and lost income) for women with 
breast cancer 0-18 months post-diagnosis.  Survey methods collected data on out-of-
pocket costs, care-giving support, paid and unpaid work reductions, and perceptions 
from participants on these financial impacts.  Bootstrapping was used to estimate 95% 
confidence intervals around means.  Data were sub-grouped by cost type, age 
category and disease severity.  Lost income, health service expenditures and lost 
unpaid work were the greatest sources of economic burden.   Women with positive 
lymph nodes reported significantly higher costs than those with negative lymph nodes 
(US$6,674 versus US$3,533, p<0.001), and younger women (≤50 years) with positive 
lymph nodes experienced costs 80% greater than older women (US$8,880 versus 
US$4,937, p<0.001).  Economic costs related to breast cancer may continue to affect 
women 18 months post-diagnosis.  Economic research adds an important dimension 
for understanding the impact of breast cancer, and findings may be used to help 
improve supportive care services for women and families confronted by this disease. 
 
Keywords:  cancer, oncology, breast, economics, costs
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Introduction 
In Australia, the likelihood of a woman being diagnosed with breast cancer is one in 
11 before age 75 years(Australian Institute of Health and Welfare (AIHW) and 
Australasian Association of Cancer Registries (AACR), 2001).  The number of new 
cases of breast cancer increased from 100.4 per 100,000 population in 1991 to 117.2 
per 100,000 population in 2001(Australian Institute of Health and Welfare (AIHW) 
and Australasian Association of Cancer Registries (AACR), 2004).  During the same 
time, mortality declined on average by 2.2% annually(Australian Institute of Health 
and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR), 
2004).  Approximately 84% of women diagnosed with breast cancer are expected to 
survive for at least five years(Australian Institute of Health and Welfare (AIHW) and 
Australasian Association of Cancer Registries (AACR), 2001).  Partly due to these 
trends of declining mortality and increasing incidence, expenditures for breast cancer 
treatment from 1993-94 to 2000-01 increased 42% (compared to 24% for all 
cancers)(Australian Institute of Health and Welfare (AIHW), 2005) and the costs of 
follow-up medical care, ongoing pharmaceutical needs and recurrences also are 
predicted to increase(Chirikos, 2001).  For women aged 25-64 years, breast cancer 
had the second highest health system expenditure of all cancers in 2000-01 in 
Australia(Australian Institute of Health and Welfare (AIHW), 2005).   
 
Although we know from regular monitoring the medical costs to the health system for 
screening, treatment and diagnosis, there is little information on the economic impact 
of breast cancer to individuals, families and the broader community.  Previous studies 
on out-of-pocket costs from breast cancer have limited application because they may 
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not reflect current treatments or health insurance coverage(Butler and Howarth, 
1999), have very small convenience samples(Moore, 1998; Butler and Howarth, 
1999; Moore, 1999) or included selective breast cancer patients(Moore, 1998; Moore, 
1999).  However, identified factors that are associated with higher individual out-of-
pocket costs include advanced disease and associated medications(Grunfeld et al., 
2004), hormone therapy, insurance gap payments, and greater traveling distances to 
the hospital(Clarke, 1998; Lauzier et al., 2005).  When family care-giving was 
monetized over a 3-month period in an all-cancer sample, the cost of family labor was 
found to be as much as nursing home care(Stommel et al., 1993).   
 
The literature on breast cancer and the impact on employment and earnings show 
varying results with positive(Satariano and DeLorenze, 1996; Bradley et al., 2002), 
neutral(Hensley et al., 2005) and negative consequences(Butler and Howarth, 1999; 
Bradley et al., 2002; Grunfeld et al., 2004; Maunsell et al., 2004) being reported.  
Adverse effects on employment and lost income appear short-term, as women resume 
normal activities over time(Satariano and DeLorenze, 1996; Bradley et al., 2002).  
However, as a consequence of breast cancer, a small percentage of women report 
early retirement (≈10%), problematic workplace re-entry(Stewart et al., 2001; 
Hensley et al., 2005), and/or refusal of insurances(Stewart et al., 2001; Hensley et al., 
2005).  The interpretation of this literature is limited because of cross-sectional 
designs, the inability to distinguish effects of ageing and life choices, and limited 
generalisability because most studies are from the US(Satariano and DeLorenze, 
1996; Bradley et al., 2002; Chirikos et al., 2002; Chirikos et al., 2002) where health 
insurance is linked to employment.  Only one study investigated lost household 
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production(Stommel et al., 1993), while one other compared the broader costs of two 
rehabilitation programs with a non-intervention group(Gordon et al., 2005).    
 
Understanding the economic impact to individuals with breast cancer (and their 
families) is important for several reasons.  Financial distress is a quality-of-life issue 
and contributes to the context in which a patient makes decisions about treatment and 
recovery(Moore, 1999).  Out-of-pocket costs may potentially cause treatment 
delays(Moore, 1999; Langa et al., 2004), particularly for women living in areas 
remote from treatment centres.  Treatment processes may incur out-of-pocket costs, 
and in turn, may affect a woman’s ability to continue working; however, these 
dynamic relationships are not well-understood(Kenny et al., 1999).  Additionally, 
employment effects, lost income and out-of-pocket costs affect the individual, her 
family and her employer. Prolonged primary and adjuvant treatment for breast cancer 
may cause greater disruption to workplace activities and earnings, at least within the 
first year of diagnosis.  Clearer information may help those diagnosed with breast 
cancer plan for anticipated costs while enabling health professionals to identify 
women who may benefit from referral to social workers and/or government support 
agencies.   
 
Furthermore, in an attempt to contain costs, hospital systems are shifting the burden 
of managing many diseases on to patients and families.  While there are many 
benefits from these changes, early discharge and outpatient care are successful only if 
individuals are adequately supported (physically, psychosocially and financially) by 
others(Davis et al., 2000).  Early discharge following breast surgery is now 
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commonplace(Burns et al., 2003), and family care-giving is a crucial part of surgical 
recovery with increasing responsibility and burden on family members(Davis et al., 
2000). The burden and social impact of breast cancer therefore is increasingly 
important to understand for contributing to health and social policies.  Finally, 
economic information for individuals may be useful for investigating cost-
effectiveness and other evaluations of health services.  Typically, these analyses do 
not include wider social costs because methods of estimation are controversial, 
outside of the budget holder’s domain, or have simply been overlooked. 
 
The aim of this paper is to report on the direct and indirect costs incurred by women 
with breast cancer over 0-18 months post-diagnosis and explore these by age and 
lymph node status (as an indicator for disease severity).  Direct costs include breast 
cancer-related health service expenditure, purchases of garments/aids and hired home 
services, and indirect costs include reductions in work activities and the use of 
informal (unpaid) care.  In Australia, despite a health care system where universal 
health insurance is provided to all citizens, and private insurance is optional, this 
research attempts to highlight the hidden costs associated with having breast cancer 
that are incurred by individuals. 
 
Methods 
A longitudinal study, entitled ‘Pulling-Through - A Breast Cancer Recovery Study,’ 
was designed to measure the prevalence and severity of upper-body limitations and 
health-related quality of life during the first 18 months from diagnosis.  Physical and 
subjective measurements of upper-body limitations were collected to establish 
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patterns of typical recovery and identify possible sub-groups requiring special needs.  
The target population was English-speaking women recently diagnosed with 
unilateral breast cancer, aged 20-75 years and who resided within a 100km radius of 
Brisbane (where approximately 70% of the Queensland population resides).  A 
population-based approach for recruitment utilized data from the Queensland Cancer 
Registry.  All women diagnosed with breast cancer in Queensland have their details 
sent to this Registry.  Random over-sampling of women aged up to 50 years enabled 
adequate numbers for separate analyses in this subgroup.  Following ethical protocols, 
consent from the treating doctor was received for 417/510 women (82%), and 296 
women (71%) agreed to be contacted by the researchers.  Of these women, 287 agreed 
to participate in the study and 272 women remained at the study’s end.  Staging 
information is unavailable from Registry records, so lymph node status was abstracted 
from pathology forms.  Relevant ethics and related approvals from the authors’ 
university and the Queensland Cancer Registry were received prior to the project’s 
commencement.  Further details on the methods, instruments and primary outcomes 
of this project have been reported previously (Hayes et al., 2005). 
 
Data collection occurred during 2002-2004 through clinical measurements and self-
administered questionnaires.  Questionnaires were obtained at five time-points 
(phases 1 to 5): 6, 9, 12, 15 and 18 months from the date of diagnosis.  Pathology 
records were abstracted to obtain specific breast cancer characteristics (e.g., surgery 
type, number of nodes removed, and tumor size).  The questionnaires covered items 
on: demographic characteristics; breast cancer treatment; symptoms; usual activities, 
associated disabilities, and availability of support and assistance; physical activity 
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levels, general health characteristics, health-related quality of life and economic 
information.   
 
No standardized or validated instrument was available to assess self-reported 
economic cost information, and therefore the authors developed these items 
(Appendix 1).   Economic questions included health service expenditure specifically 
attributable to breast cancer using prompts (e.g., medical practitioner visits, 
physiotherapist visits, etc.), physical and social support programs undertaken, the use 
and cost of domestic services, family and other care-giving support, out-of-pocket 
expenses (e.g., wigs, customized bras, prosthetics, lymphedema sleeve, etc.), paid and 
unpaid work reductions and associated lost income.  The questionnaire was pre-tested 
among 10 colleagues and 10 breast cancer survivors, and this testing supported the 
face and content validity of the economic questions. 
Analysis 
The analysis was intended to be descriptive and exploratory rather than inferential. 
The perspective of the survivor was taken for the analysis, and government outlays or 
third party co-payments were not included.  Costs were adjusted for inflation using 
the Health Price Index (using an annual percentage rate of 2.4%(Australian Institute 
of Health and Welfare (AIHW), 2001)) and brought forward to 2005 (Australian) 
dollars.  Results have been converted to 2005 US dollars using the purchasing power 
parity A$1 = US$0.75(Organisation for Economic Cooperation and Development, 
2006).  
Cost items were quantified directly from survey responses and may or may not have 
been abstracted from other sources (e.g., receipts).  Direct costs included out-of-
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pocket expenditure on garments and aids, health services (e.g. co-payments, 
pharmaceuticals) and paid home services.  Indirect costs included the value of lost 
income, unpaid help, and lost unpaid work.  Days of unpaid or paid work lost were 
self-reported, and for paid work were adjusted for any employer leave benefits.  
Number of days lost were converted to hours based on a 38-hour week for full-time 
workers.  This conversion was necessary to accommodate part-time or occasional 
working situations more common among women.  The average weekly earnings for 
women in Queensland were used to value lost income from hours lost from paid 
employment(Australian Bureau of Statistics, 2003).  Unpaid work was categorized 
into two broad types: production by households for their own consumption (e.g., a 
family member providing care for another family member), and volunteer, charity or 
community work provided free of charge to others outside the family.  Although the 
distinctions between unpaid work and leisure are sometimes blurred and certainly 
debatable, unpaid work was defined here as those activities recognized by the study 
participants as time-committed and valued activities within their community that 
otherwise could be purchased from the market sector(Australian Bureau of Statistics, 
1997).  Examples of unpaid work in our sample included: caring for children and 
other family members, volunteer work (at schools, hospitals, and caring 
organizations), office work in a family business and tutoring. The quantities of unpaid 
work were valued with an hourly estimate using the ‘net opportunity cost 
approach’(Australian Bureau of Statistics, 1997).  This estimate was used to reflect 
the survivors’ value of what they could have earned in wages (including employer 
benefits) had they spent the same amount of time in paid work as expended on unpaid 
work after allowing for tax and any work-related costs. 
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Cost data are often skewed, with many participants having zero or minimal values and 
a small proportion of participants having very high values.  Descriptive statistics 
showing cost distributions (i.e., means, standard deviations, medians, minimums and 
maximums) and sums are presented.  Data are summarized for direct, indirect and 
total costs and presented separately for all participants and those participants with 
positive values (i.e., costs were greater than zero).  For the complete sample, a zero 
cost was used for participants who reported a ‘no’ response to cost questions or failed 
to respond to that question.  This imputation for those with missing data was 
considered reasonable given the relatively high response rates and proportions of 
women incurring no cost for any particular item (see Results section).  In addition, 
using the original data, bootstrapped means and 95% confidence intervals (95% CIs) 
using the bias-corrected-accelerated approach were calculated from re-sampling the 
data 1,000 times(Efron and Tibshirani, 2003).  Bootstrapped means and 95% CIs were 
produced for each cost type (i.e., health service expenditure, out-of-pocket expenses, 
home services and productivity lost). Proportions of each cost type to total cost were 
used to help gauge the relative magnitude of each cost component.  Data were 
stratified by sub-groups of women younger or older than 50 years and by disease 
severity, defined as local (0 lymph nodes invaded) or regional (≥1 nodes invaded) 
disease.  All bootstrapped means, 95% CIs, and t-tests for significant differences of 
the mean costs involved data for those participants who reported positive values.  The 
analysis used SPSS Version 13.0 (SPSS, 2000). 
Results 
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Demographic and clinical characteristics were similar between participants and those 
in the age-stratified random sample of Queensland women from which our sample 
was recruited (Hayes et al., 2005)(Table 1).  However, the women in this study were 
mainly professionals or had white-collar occupations (69%), tertiary education (44%) 
and were relatively financially comfortable (i.e., 70% had private health insurance and 
33% had annual household incomes over AUS$52,000)(Table 1).  The weighted mean 
age of the sample was 57 years; this is younger than the most common age group for 
all Queensland women with breast cancer (65-69 years)(Queensland Cancer Registry 
and Queensland Cancer Fund, 2005), as expected due to stratified sampling in the 
study design.   
 
[Insert Table 1 here] 
 
Response rates for the individual economic survey questions ranged from 85-99% 
across the five phases.  The question on health service expenditure had the lowest 
response rates at each phase (85-92%) but also had the highest proportions of ‘yes’ 
responses for incurring costs (29-54% across all phases).  At any one phase, over 50% 
of the participants incurred no cost for hired help, garments, support programs, paid or 
unpaid work reductions. 
 
Table 2 presents a summary of overall costs for the time period 0-18 months post-
diagnosis.  The total value of costs incurred for the 287 women in the study was 
$1,322,775 with a weighted median of $1,781 per person (min $0, max $43,727).  For 
25% of the sample, total economic losses were valued at <$567 while for the top 5% 
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of the sample, this figure was >$18,145.  Nearly all women reported some economic 
loss (92%), while 252 women (88%) reported direct costs (health services or 
garments/aids or home services) with a median of $827 and 184 women (64%) 
reported indirect costs (unpaid or paid work reductions or unpaid help) valued at a 
median of $148. 
 
[Table 2 about here] 
 
Figure 1 illustrates the weighted median costs for each 6-month period for women 
reporting positive costs.  The greatest burden for women was apparent early after 
diagnosis, particularly during the first six months (total cost median $1,453, min $20, 
max $31,440); this burden gradually declined over the following months and was 
substantially lower by 13-18 months (median $484, min $6, max $16,622).  Health 
services expenditure peaked at 7-12 months (median $420, n= 177) and was higher at 
13-18 months (median $368, n= 145) than at 0-6 months (median $263, n= 151).  
Lost income, the most substantial source of cost at each time period, steadily declined 
in value from a median of $5,078 (n=73) during 0-6 months to a median of $1,553 
(n=23) during 13-18 months.  The value of lost unpaid work also remained relatively 
high over time but also declined in value, from a median of $2,380 (n=33) to $1,433 
(n=14) during 0-6 months and 13-18 months, respectively.  The cost of purchasing 
garments and aids peaked at 0-6 months, with a median of $216 (n=129), and home 
services costs increased from a median of $164 (n=57) at 0-6 months to $208 (n=41) 
by 13-18 months. 
[Figure 1 here] 
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Bootstrapped means with 95%CIs are provided in Tables 3 and 4.  The most 
substantial costs to women, as a proportion of total costs, included lost income, health 
service expenditures and lost unpaid work (Table 3).  There were significantly higher 
costs for all items for women ≤50 years than for those >50 years.  The mean value of 
total indirect costs was higher for younger compared to older women, $3,853 versus 
$2,230 (p<0.001), respectively, and similar results were found for direct costs for 
younger and older women, $2,099 versus $1,599 (p<0.001), respectively. 
 
[Table 3 here] 
 
Women with positive lymph nodes reported nearly twice the costs of women with 
negative lymph nodes: $6,674 versus $3,533 (p<0.001)(Table 4 and Figure 2).  Direct 
costs were more frequently reported than indirect costs for women irrespective of 
nodal status, but the value of indirect costs were higher.  When analyses were 
stratified by age category and nodal status, younger women with positive nodes had 
average total costs 80% greater than older women with invaded nodes, $8,880 versus 
$4,937 (p<0.001), respectively.  Younger women with negative nodes had average 
total costs 67% greater than older women with negative nodes, $4,819 versus $2,891, 
p<0.001.  Only total direct costs were similar for younger women with negative nodes 
and older women with positive nodes, $1,820 versus $1,797 (p=0.23), respectively. 
 




This is the first known study to quantify the economic burden on women with breast 
cancer over time from a population-based sample and include out-of-pocket expenses, 
reductions in non-market production and income losses.  Furthermore, it is the only 
study that has investigated personal costs by age category and disease severity.  
Although there was great variability in the absolute values, most women reported 
some economic loss by 18 months after their diagnosis.  Lost income was the greatest 
source of financial burden followed by out-of-pocket costs for health services and lost 
unpaid work.  Over time, overall costs for women with breast cancer declined in 
value.  However, as many women began returning to work, and therefore faced 
reduced losses in income, several sources of costs remained ongoing (i.e., health 
services, garments/aids and losses in unpaid work). 
 
Health care funding within Australia involves a combination of universal health 
insurance that is provided to all citizens and optional private insurance.  These 
arrangements are also similar to the Canadian and some European health care 
systems.  In the US, the Medicare and Medicaid programs insure older citizens for 
health care but no national health service or insurance exists, and health insurance is 
most often organized through employers.  Individuals in both countries also make co-
payments or out-of-pocket payments for health services, and trends in Australia 
suggest these contributions are increasing(Australian Institute of Health and Welfare 
(AIHW), 2004).  In the US, it has also been found that older persons with cancer face 
significant out-of-pocket expenses mainly for medications and home services(Langa 
et al., 2004).  The findings from our study highlight that women are faced with 
 15
relatively high proportions of personal health care expenditures and additional hidden 
costs, despite most being covered by private health insurance.  Costs for health 
services were ongoing for a significant proportion of women up to 18-months after 
the initial diagnosis, when surveillance ceased, and remained at a level similar to 
those for 7-12 months. 
 
In our study, women with more severe disease (positive lymph nodes) had 
significantly higher costs than women with no nodal involvement.  Intuitively, women 
with more advanced disease would likely face greater health service needs and 
associated costs through greater contacts with doctors, medical tests and routine 
follow-up care.  However, this study also highlights the additional indirect economic 
burden placed on women with more severe disease to deal with these commitments.  
 
Our study found younger women were especially vulnerable in terms of larger 
economic burden after breast cancer diagnosis, particularly those with positive nodes.  
This appeared to be mainly due to larger health service costs and reductions in unpaid 
work activities (i.e., household production, childcare, school or community volunteer 
work, etc.).  Greater numbers of younger women reported incurring income losses but 
generally had lower values of these losses than older women.  Conversely, for unpaid 
work reductions, fewer younger women reported losses but the value was higher than 
their older counterparts.  This could be explained by greater numbers of younger 
women facing part-time work, lower paid jobs and/or greater competing home and 
children commitments compared to older women.  Similarly, a recent study by 
Hensley et al. (2005) found that younger women incurred higher medical costs than 
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women in general with breast cancer(Hensley et al., 2005).  Their sample was 
comprised of women with stage II disease, all undergoing chemotherapy, and 95% of 
younger women (<50 years) were found to over-utilize medical practitioner care and 
follow-up tests after their breast cancer diagnosis(Hensley et al., 2005). 
 
In 2001, 63% of all new cases of breast cancer among Australian women were 
diagnosed during working ages (<65 years)(Australian Institute of Health and Welfare 
(AIHW) and Australasian Association of Cancer Registries (AACR), 2004).  Lost 
unpaid work, comprised of household production losses, may be of particular concern 
because regardless of whether a woman is working or not, household production 
traditionally falls on women. The results here reflect the extra burden faced by 
younger (working-age) women.  The strain on families to provide care and 
compensate lost household production by the cancer survivor may be a growing 
problem given the age demographics of the cancer population (i.e., increasing 
diagnosis among younger women), the social trend towards smaller households, later 
childbearing and isolation from family networks (Stommel et al., 1993).  
 
This study highlights the double-edged sword of breast cancer in financial terms, with 
families facing greater medical and other expenses while at the same time losing 
household income. Potentially, this may lead to substantial financial strain, 
particularly if women are casually or self-employed (Butler and Howarth, 1999; 
Bradley et al., 2002; Grunfeld et al., 2004; Maunsell et al., 2004; Lauzier et al., 2005).  
A qualitative Canadian study by Lauzier et al. (2005) emphasized the financial burden 
felt by women particularly due to disrupted roles, reduced income and higher medical 
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costs (Lauzier et al., 2005).  The authors stressed that it is not the dollar value per se 
that is of prime concern, but rather, the perception of financial strain and coping with 
an unwanted change in economic circumstances (Lauzier et al., 2005). 
 
This study has some shortcomings.  Like previous research in this area, the analysis is 
exploratory and relies on self-reported survey data with the associated potential for 
recall bias.  Unfortunately these economic data are unavailable from more objective 
sources (except some health service items via administrative databases), which 
necessitates survey methods.  Balanced against this is the intentional purpose to 
obtain data from the perspective of the women. Data collection at 3-monthly intervals 
helped minimize the duration of participant recall, however validation against receipts 
was considered too onerous to request.  Although changes in income and hours of 
work were directly assessed, other pertinent information on changes in work status, 
insurance and employment effects were not assessed to further avoid increased 
participant burden.  Furthermore, paid and unpaid productivity has been separately 
categorized under indirect costs due to conceptual and measurement controversies in 
this area(Sculpher, 2001).  For brevity, travel and accommodation costs were not 
specifically asked of women, but may have been considered and incorporated in 
responses to other questions.  We did not expect these to be high due to the sample 
being urban and largely local to their treatment centres.  The results of this study may 
underestimate costs to women with breast cancer living in rural or remote areas and 
the associated traveling and accommodation expenses that these women incur(Clarke, 
1998; Lauzier et al., 2005).  Lastly, the results of this study may have limited 
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generalisability with respect to absolute costs, but the relative proportions in the cost 
categories may be similar across countries with similar modes of health care. 
 
Treatment for breast cancer has a rippling effect through the community as each 
woman’s life is challenged, with frequent interruptions in her usual (often multiple) 
role activities, including family functioning, employment and other societal 
commitments.  This paper serves to highlight these hidden and ongoing costs faced by 
breast cancer survivors, to inform interested parties of the nature and extent of patient 
costs of breast cancer, and to build on what is currently known about costs to 
survivors around the time of diagnosis and treatment.  
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Appendix 1  Economic questions used for data collection 
 
(insert Appendix 1 PDF file here) 
 
Footnote to Appendix 1: 
Please note, the questions within Q21 are limited.  These relate to direct expenses for 
out-of-pocket costs, aids and garments and would be significantly improved in future 
work if they provided itemised yes/no boxes for each known component, associated 
quantities and costs per unit quantity.  In addition, since this project started, two 
additional standardised tools for employment and out-of-pocket costs are available: 
(1) the Work Productivity and Activity Impairment (Reilly Associates, 2002) survey 
and (2) the Collection of Indirect and Nonmedical Direct Costs (COIN) form 
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n  287 510 
Age  - weighted mean (SD) 57 (9.6) 53 
    Younger (≤50 yrs) 108 (38%) 42% 
    Older (>50 yrs) 179 (62%) 58% 
Education(a)   
   Primary 28 (10%) - 
   Secondary 130 (45%) - 
   Tertiary 127 (44%) - 
Occupation group   
   Professional 103 (36%) - 
   White collar 95 (33%) - 
   Blue collar 11 (4%) - 
   Homemaker 34 (12%) - 
   Retired/Student 19 (7%) - 
Household income   
   < A$26,000 p.a. 84 (29%) - 
    A$26,000 – 51,999 p.a. 73 (25%) - 
    >A$52,000 p.a. 94 (33%) - 
Health insurance   
     Yes 202 (70%) - 
     No 84 (29%) - 
Surgical treatment(b)   
     Mastectomy 78 (27%) 28% 
     Breast-conserving   209 (73%) 73% 
     Axillary dissection 249 (87%) - 
Adjuvant therapy(b)    
     Radiation  205 (71%) - 
     Chemotherapy  121 (42%) - 
     Hormone therapy  117 (41%) - 
Tumor size    
     Median, mm (min, max) 17 (0.5, 140) 14 (0.3, 230) 
Lymph node status(a)    
   Median, number (min, max) 0 (0-39) 0 (0-39) 
    0 nodes invaded 158 (55%) - 
    ≥ 1 nodes invaded(c) 91 (32%) - 
Complications(b)   
    Wound or other  infection 45 (16%) - 
    Skin/tissue reaction 148 (52%) - 
    Arm swelling 71 (25%) - 
    Seroma/hematoma 47 (16%) - 
(a) Missing data – Health insurance 1 (0.3%); Household income 36 (13%); Occupation group 25 (9%); Education 2 (0.7%); Nodal 
status 38 (13%) (b) Not mutually exclusive categories (c)This category includes: 1-3 nodes 59 (21%); 4-9 nodes 18 (6%); >10 nodes 
14 (5%) 
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Table 2.   Summary of survivor costs related to breast cancer (0-18 months post-diagnosis) 
by broad cost category ($US 2005)(a) 
 
Cost Category n % total n Mean $ Sd $ Median $ Min $ Max $ Sum $ 
Direct          
 





         
1,937  
         
3,210  
         
827  
         
-    
         
 
24,338  
          
          
 
506,411  
           
 




 88  
         
1,688  
         
3,065  
         
605  
         
4  
Indirect                            
 





         
4,221  
         
6,093  
         
1,821  
         
-    
         
 
33,350  
          
          
 
816,363  
           
 





         
2,609  
         
5,208  
         
148  
         
5  
Total                             
 
- all women 
 
 287  
  
100  
         
4,689  
         
7,029  
         
1,781  
         
-    
         
 
43,727  
          





- women with $>0 
 
 265  
 
 92  
         
4,297  
         
6,853  
         
1,518  
         
4  
 
(a) Costs have been weighted to compensate for oversampling of younger women.
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Table 3.   Summary of survivor costs of breast cancer (0-18 months post-diagnosis) among 
all participants and separately by age categorya ($US 2005) 
 





All participants (N=265)b           
  Health services 214          1,317          1,329          1,016          1,679  
  Garments/aids 162             245             245             200             292  
  Paid home services 85             186             191             112             291  
  Total direct costs 252          1,760          1,762          1,416          2,111  
  Unpaid help 138             329             332             208             446  
  Lost income 92          1,891          1,901          1,369          2,435  
  Lost unpaid work 52             614             625             358             890  
  Total indirect costs 185          2,821          2,845          2,300          3,509  
    Total costs 265          4,575          4,595          3,815          5,474  
Agec      
  ≤50 years (N=103)      
  Health services 90          1,526          1,531          1,048          1,992  
  Garments/aids 62             276             278             201             365  
  Paid home services 34             269             281             110             491  
  Total direct costs 98          2,091          2,099          1,570          2,635  
  Unpaid help 58             415             429             217             667  
  Lost income 52          2,483          2,503          1,727          3,346  
  Lost unpaid work 20             919             938             311          1,547  
  Total indirect costs 82          3,851          3,853          2,700          4,991  
    Total costs 103          5,924          5,951          4,622          7,395  
  >50 years (N=162)           
  Health services 124          1,205          1,216             772          1,632  
  Garments/aids 100             222             224             177             278  
  Paid home services 51             134             135               70             209  
  Total direct costs 154          1,553          1,566          1,130          2,038  
  Unpaid help 80             269             275             155             401  
  Lost income 40          1,499          1,522             914          2,196  
  Lost unpaid work 32             423             427             251             616  
  Total indirect costs 103          2,229          2,230          1,504          2,956  
    Total costs 162          3,781          3,815          2,855          4,826  
 
a.  Results weighted to compensate for over-sampling of younger women. 
b.  Participants reporting values >$0. 
c.  Mean costs were significantly different (p<0.001) between age ≤50 versus age >50  





Table 4.   Direct, indirect and total costs by status of lymph node involvement overalla  
and stratified by age category ($US 2005) 
 





All women c      
 Local - 0 invaded nodes (N=143)    
  Total direct costs 138 1,440 1,450 1,090 1,820 
  Total indirect costs 93 2,061 2,072 1,379 2,856 
  Total costs 143 3,486 3,533 2,667 4,591 
 Regional - ≥ 1 invaded nodes ( N=85)    
  Total direct costs 80 2,363 2,387 1,710 3,155 
  Total indirect costs 68 4,331 4,354 3,007 5,718 
    Total costs 85 6,640 6,674 5,136 8,515 
Younger womend      
 Local - 0 invaded nodes (N=48)    
  Total direct costs 46 1,800 1,820 1,130 2,534 
  Total indirect costs 35 3,022 3,066 1,565 4,628 
  Total costs 48 4,755 4,819 3,219 6,986 
 Regional ≥ 1 invaded nodes (N=40)     
  Total direct costs 39 3,117 3,138 2,120 4,203 
  Total indirect costs 36 5,706 5,728 3,864 7,775 
  Total costs 40 8,843 8,880 6,701 11,204 
Older womend           
 Local - 0 invaded nodes (N=95)    
  Total direct costs 92 1,256 1,259 872 1,730 
  Total indirect costs 58 1,580 1,613 965 2,432 
  Total costs 95 2,867 2,891 1,961 3,870 
 Regional ≥ 1 invaded nodes (N=45)    
  Total direct costs 41 1,747 1,797 830 2,649 
  Total indirect costs 32 3,120 3,173 1,443 4,919 
    Total costs 45 4,868 4,937 2,482 7,177 
 
a.  Nodal status is known for 246 women; 38 women did not have nodes removed  
and 3 had nodes removed but status is unknown. 
b.  Participants reporting values >$0.  All results weighted to compensate for over-sampling of 
younger women. 
c. Mean costs were significantly different between local and regional disease groups for  
all costs (p<0.001). 
d. Mean costs were significantly different between younger and older women within 










Figure 1.  Median costs1 by main source2 in each 6-month period 












Months 0-6 Months 7-12 Months 13-18 
Lost unpaid work (n=33 at 6m, n=31 at 7-12m, n=14 at 13-18m)
Lost income (n=73 at 6m, n=44 at 7-12m, n=23 at 13-18m)
Other out-of-pockets (n=129 at 6m, n=114 at 7-12m, n=81 at 13-18m)
Health services (n=151 at 6m, n=177 at 7-12m, n=145 at 13-18m)
 
 
1. Participants reporting values >$0. Figures are weighted to account for over-sampling of younger women. 
 





Figure 2.  Mean costs1  and 95%CIs by age category and lymph node status 
















Younger  Older Younger Older 
No invaded nodes Invaded nodes




1. Participants reporting values >$0.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
